How about AXON's 1.3 Billion market cap for a company whose sole asset is a failed Alzheimer's drug that they purchased from Big Pharma -- no human trials yet because they just started operation and don't really have any significant number of staff, and this is a drug that already failed once -- in a category that is becoming crowded and being recognized as the wrong approach to treat the disease.

Oh I forgot the other asset they have:
They are run and hyped by young, well-connected Wall Street insiders. The IPO was 3 Billion -- so already, since last summer, it's lost a huge amount of value. At these levels, it's now only 100% overpriced. hahahaha